Pharma

Your Article Summary

See Latest Articles

Taro Receives FDA Approval for Sulfacetamide Sodium Topical Suspension ANDA
Taro Pharmaceuticals USA, 05/22/09

Taro Pharmaceutical Industries Ltd. reported that its Canadian manufacturing site has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Sulfacetamide Sodium Topical Suspension USP, 10%.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

 See all of Drug/Product Approvals